Exact Sciences (EXAS) Competitors $44.99 +0.07 (+0.16%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$44.80 -0.19 (-0.42%) As of 03/27/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, UTHR, BMRN, INCY, NBIX, EXEL, RGEN, HALO, MDGL, and ALKSShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Alkermes (ALKS). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alkermes Biogen (NASDAQ:BIIB) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings. Is BIIB or EXAS more profitable? Biogen has a net margin of 16.87% compared to Exact Sciences' net margin of -37.29%. Biogen's return on equity of 14.98% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen16.87% 14.98% 8.76% Exact Sciences -37.29%-5.29%-2.45% Does the MarketBeat Community favor BIIB or EXAS? Biogen received 829 more outperform votes than Exact Sciences when rated by MarketBeat users. However, 73.11% of users gave Exact Sciences an outperform vote while only 71.47% of users gave Biogen an outperform vote. CompanyUnderperformOutperformBiogenOutperform Votes181671.47% Underperform Votes72528.53% Exact SciencesOutperform Votes98773.11% Underperform Votes36326.89% Which has more risk and volatility, BIIB or EXAS? Biogen has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Do analysts recommend BIIB or EXAS? Biogen currently has a consensus price target of $213.33, suggesting a potential upside of 52.02%. Exact Sciences has a consensus price target of $70.83, suggesting a potential upside of 57.44%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Exact Sciences is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 17 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.43Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has better valuation & earnings, BIIB or EXAS? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.12$1.63B$11.1912.54Exact Sciences$2.76B3.03-$204.15M-$5.57-8.08 Does the media refer more to BIIB or EXAS? In the previous week, Biogen had 17 more articles in the media than Exact Sciences. MarketBeat recorded 29 mentions for Biogen and 12 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 1.09 beat Biogen's score of 1.08 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 20 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of BIIB or EXAS? 87.9% of Biogen shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 1.4% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryBiogen and Exact Sciences tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.36B$2.88B$5.64B$8.06BDividend YieldN/A22.57%4.57%4.02%P/E Ratio-8.0813.2523.1319.03Price / Sales3.03205.58383.8993.17Price / Cash8.7957.5638.1634.64Price / Book3.484.526.944.33Net Income-$204.15M-$22.21M$3.20B$247.06M7 Day Performance1.60%-2.02%-2.30%-0.52%1 Month Performance-5.92%-2.40%3.10%-3.73%1 Year Performance-32.73%1.02%11.22%1.74% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.5798 of 5 stars$44.99+0.2%$70.83+57.4%-32.7%$8.36B$2.76B-8.086,400News CoveragePositive NewsBIIBBiogen4.9116 of 5 stars$141.60+0.5%$213.33+50.7%-35.1%$20.73B$9.68B12.658,720Positive NewsUTHRUnited Therapeutics4.9404 of 5 stars$319.86+2.2%$388.25+21.4%+26.6%$14.37B$2.88B14.05980Insider TradeShort Interest ↓Positive NewsBMRNBioMarin Pharmaceutical4.9038 of 5 stars$71.99+1.1%$94.00+30.6%-17.8%$13.73B$2.85B32.723,401Options VolumeINCYIncyte4.7096 of 5 stars$62.78+1.4%$74.88+19.3%+6.2%$12.15B$4.24B232.532,617Positive NewsNBIXNeurocrine Biosciences4.9292 of 5 stars$115.64+3.3%$165.24+42.9%-17.3%$11.53B$2.36B35.151,200Analyst ForecastNews CoveragePositive NewsEXELExelixis4.5566 of 5 stars$37.72+2.1%$37.59-0.3%+54.4%$10.56B$2.17B21.311,220Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsRGENRepligen4.7538 of 5 stars$145.15+3.7%$178.64+23.1%-25.8%$8.15B$634.44M-284.612,020Positive NewsHALOHalozyme Therapeutics4.283 of 5 stars$64.02-1.7%$62.78-1.9%+58.3%$7.91B$1.02B18.66390Positive NewsMDGLMadrigal Pharmaceuticals3.5502 of 5 stars$346.40+1.4%$378.44+9.3%+30.3%$7.65B$180.13M-13.8190Positive NewsALKSAlkermes4.6331 of 5 stars$34.84+0.7%$38.46+10.4%+23.0%$5.67B$1.56B16.051,800Analyst ForecastNews CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives BioMarin Pharmaceutical Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Alkermes Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXAS Stock Free EXAS Stock Alerts